{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:03:33Z","timestamp":1794639813595,"version":"4.9.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Indivior, Inc. (Richmond, Virginia)"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.drugalcdep.2018.09.007","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T17:51:35Z","timestamp":1539366695000},"page":"117-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["Understanding the use of diverted buprenorphine"],"prefix":"10.1016","volume":"193","author":[{"given":"Theodore J.","family":"Cicero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard D.","family":"Chilcoat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.drugalcdep.2006.09.012","article-title":"Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users","volume":"88","author":"Alho","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/ADM.0b013e3182034e31","article-title":"Illicit use of buprenorphine\/naloxone among injecting and noninjecting opioid users","volume":"5","author":"Bazazi","year":"2011","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0015","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0196-9781(00)00252-7","article-title":"Agonistic effects of the opioid buprenorphine on the nociceptin\/OFQ receptor","volume":"21","author":"Bloms-Funke","year":"2000","journal-title":"Peptides"},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/00952990802585406","article-title":"Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine\/naloxone to the Malaysian market","volume":"35","author":"Bruce","year":"2009","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1526-4637.2006.00259.x","article-title":"The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS)","volume":"8","author":"Cicero","year":"2007","journal-title":"Pain Med."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0030","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/pds.1452","article-title":"Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States","volume":"16","author":"Cicero","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0035","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.drugalcdep.2014.06.005","article-title":"Factors contributing to the rise of buprenorphine misuse: 2008\u20132013","volume":"142","author":"Cicero","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0040","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1360-0443.2009.02843.x","article-title":"Abuse liability of intravenous buprenorphine\/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers","volume":"105","author":"Comer","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0045","unstructured":"Comprehensive Addiction and Recovery Act (CARA) of 2016, Public law no. 114-198, Stat. 695 (2016)."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5694\/j.1326-5377.2009.tb02729.x","article-title":"Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation","volume":"191","author":"Degenhardt","year":"2009","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0060","first-page":"1573","article-title":"Managing opioid addiction with buprenorphine","volume":"73","author":"Donaher","year":"2006","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0065","unstructured":"Drug Addiction Treatment Act (DATA) of 2000, Public law no. 106-310, Stat. 1101 (2000)."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0070","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00228-011-1122-4","article-title":"Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning","volume":"68","author":"Hakkinen","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1477-7517-10-24","article-title":"\u2018Diversion\u2019 of methadone or buprenorphine: \u2018Harm\u2019 versus \u2018helping.\u2019","volume":"10","author":"Havnes","year":"2013","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","article-title":"Why aren\u2019t physicians prescribing more buprenorphine?","volume":"78","author":"Huhn","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0090","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1370\/afm.1595","article-title":"Barriers to primary care physicians prescribing buprenorphine","volume":"12","author":"Hutchinson","year":"2014","journal-title":"Ann. Fam. Med."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugpo.2014.10.003","article-title":"Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors","volume":"26","author":"Johnson","year":"2015","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0100","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1300\/J069v25n04_09","article-title":"Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence","volume":"25","author":"Kissin","year":"2006","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/ADM.0000000000000360","article-title":"Physicians\u2019 decision-making when implementing buprenorphine with new patients: conjoint analyses of data from a cohort of current prescribers","volume":"12","author":"Knudsen","year":"2018","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0955-3959(99)00057-2","article-title":"Rapid assessment and response to injecting drug use in Madras, South India","volume":"11","author":"Kumar","year":"2000","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/08897077.2012.752777","article-title":"A buprenorphine education and training program for primary care residents: implementation and evaluation","volume":"34","author":"Kunins","year":"2013","journal-title":"Subst. Abuse"},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/dar.12344","article-title":"Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia","volume":"35","author":"Larance","year":"2016","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsat.2014.02.003","article-title":"Abuse and diversion of buprenorphine sublingual tablets and film","volume":"47","author":"Lavonas","year":"2014","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0135","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drugalcdep.2012.05.025","article-title":"Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine","volume":"126","author":"Lofwall","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0140","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world","volume":"8","author":"Lofwall","year":"2014","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/157488611794480034","article-title":"Accidental and non-accidental ingestion of methadone and buprenorphine in childhood: a single center experience, 1999\u20132009","volume":"6","author":"Martin","year":"2011","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0740-5472(03)00247-2","article-title":"Training rural practitioners to use buprenorphine; using The Change Book to facilitate technology transfer","volume":"26","author":"McCarty","year":"2004","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0155","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jsat.2014.02.001","article-title":"The affordable care act and treatment for \u201csubstance use disorders:\u201d implications of ending segregated behavioral healthcare","volume":"46","author":"McLellan","year":"2014","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0160","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/10550880903014767","article-title":"Diversion of buprenorphine\/naloxone coformulated tablets in a region with high prescribing prevalence","volume":"28","author":"Monte","year":"2009","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0165","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1097\/PCC.0b013e3181f3a118","article-title":"Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine\/naloxone","volume":"12","author":"Pedapati","year":"2011","journal-title":"Pediatr. Crit. Care Med."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0170","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s002130050066","article-title":"Effects of buprenorphine versus buprenorphine\/naloxone tablets in non-dependent opioid abusers","volume":"148","author":"Strain","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0175","unstructured":"Substance Abuse and Mental Health Services Administration, Medication-assisted treatment physician: Physician and program data [WWW Document]. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/physician-program-data (Accessed 12 January 2018)."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0180","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jat\/22.6.430","article-title":"Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities","volume":"22","author":"Tracqui","year":"1998","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0185","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.drugalcdep.2010.03.014","article-title":"Injection of buprenorphine and buprenorphine\/naloxone tablets in Malaysia","volume":"111","author":"Vicknasingam","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0190","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s11606-008-0686-x","article-title":"Office-based management of opioid dependence with buprenorphine: clinical practices and barriers","volume":"23","author":"Walley","year":"2008","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0195","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/10550887.2012.694597","article-title":"Medication-assisted recovery from opioid addiction: historical and contemporary perspectives","volume":"31","author":"White","year":"2012","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2018.09.007_bib0205","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","article-title":"Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: an international review","volume":"4","author":"Yokell","year":"2011","journal-title":"Curr. Drug Abuse Rev."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618307245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618307245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:06:46Z","timestamp":1605226006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871618307245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":41,"alternative-id":["S0376871618307245"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.09.007","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the use of diverted buprenorphine","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}